Your Health. Your Family. Your Choice.
Administered by: Other Purchased by: ?
Life Threatening? No
Write-up: Fever at 40 degree C; Breath shortness; Chronic obstructive pulmonary disease; erysipelas; sepsis; This is a spontaneous report from a contactable physician downloaded from the regulatory authority-WEB, regulatory authority number FR-AFSSAPS-MP20210291. An 83-year-old male patient received first dose of BNT162B2 (COMIRNATY, Solution for injection, lot/batch number not provided), intramuscular on 29Jan2021 (at unspecified age) at single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. No History of COVID-19. Patient considered to be at risk of developing a severe form of COVID-19 disease. Patient vaccinated as part of the COVID-19 vaccination campaign. Patient was hospitalized on unknown date for decompensation of COPD (Chronic obstructive pulmonary disease) and erysipelas, both events occurred on 07Feb2021 and were treated with Augmentin (amoxicillin/clavulanic acid) on a probabilistic basis. Patient was hospitalized on unknown date for Breath shortness (07Feb2021). Death 08Feb2021 in a context of sepsis (08Feb2021). Patient was hospitalized on unknown date for Fever at 40 degree C (08Feb2021). The patient underwent lab tests and procedures which included 07Feb2021: Normal scanner. 08Feb2021: Fever at 40 degree C motivating the carrying out of blood cultures in front of a probable sepsis in the context of erysipelas. 08Feb2021: Blood cultures positive for Pseudomonas aeruginosa. Death 08Feb2021 in a context of sepsis (08Feb2021). The patient died on 08Feb2021. It was unknown if an autopsy was performed. The outcome of the event sepsis was fatal, for other events was not recovered. No follow-up attempts are possible; information about lot/batch number cannot be obtained.; Reported Cause(s) of Death: sepsis
Copyright © 2021 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166